By targeting IL-13, dupilumab may reduce inflammation, restore skin barrier function, and regulate sebocyte activity, offering a novel approach to mitigating acne pathogenesis through modulation of the IL-13-IL13RA1 axis. This evidence concerns the gene IL13RA1 and acne.